



(51) International Patent Classification:

C07K 16/18 (2006.01) A61P 37/06 (2006.01)
C07K 16/24 (2006.01) A61K 39/00 (2006.01)
A61P 17/06 (2006.01)

(21) International Application Number:

PCT/EP2020/052481

(22) International Filing Date:

31 January 2020 (31.01.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

19154852.8	31 January 2019 (31.01.2019)	EP
19154846.0	31 January 2019 (31.01.2019)	EP
19154850.2	31 January 2019 (31.01.2019)	EP

(71) Applicant: **NUMAB THERAPEUTICS AG** [CH/CH];
Einsiedlerstrasse 34, 8820 Wädenswil (CH).


(72) Inventors: **URECH, David**; Sonnenblickstrasse 8, 8645 Jona (CH). **GUNDE, Tea**; Turbinenstrasse 33, 8005 Zurich (CH). **MEYER, Sebastian**; Kirchrainstrasse 6, 5445 Eggenwil (CH). **HESS, Christian**; Uetlibergstrasse 304, 8045 Zurich (CH).

(74) Agent: **BERNHARD, Virnekäs**; WALLINGER RICKER SCHLOTTER TOSTMANN, Patent- und Rechtsanwälte, Partnerschaft mbB, Zweibrückenstraße 5-7, 80331 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: MULTISPECIFIC ANTIBODIES HAVING SPECIFICITY FOR TNFA AND IL-17A, ANTIBODIES TARGETING IL-17A, AND METHODS OF USE THEREOF

Figure 12:



(57) Abstract: The present invention relates to an isolated multispecific antibody comprising a first domain specifically binding TNF α and a second domain specifically binding IL-17A and, optionally, a third domain specifically binding human serum albumin. The present invention furthermore relates to an isolated antibody which specifically binds human IL-17A. Additionally, the present invention further relates to methods of use of said antibodies, pharmaceutical compositions and methods of use thereof, and a kit comprising said antibodies. The present invention also relates to a nucleic acid comprising a nucleotide sequence encoding said antibodies, a vector comprising said nucleic acid, a host cell comprising said nucleic acid or said vector, and a method of producing said antibodies.

[Continued on next page]

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))